Centrum Medyczne Neuromed Sp. z o.o. — Clinical Trial Site

46 Registered trials

18 Currently recruiting

Organisation

Centrum Medyczne Neuromed Sp. z o.o.

Location

Bydgoszcz, Poland

Identifier

ORG-100043348

Address

Ul. Jana Biziela 14, 85-163, Poland

Departments

-
#40694: N/A
#40707; Neurology
#40707: Neurology
616004: neurology
Centrum Medyczne NEUROMED
Centrum Medyczne Neuromed Sp z o.o
Centrum Medyczne Neuromed Sp.z o.o
N/A
NA
Neurology
not applicable/nie dotyczy

Clinical trials at this site (46)

Search interface

A study of safety and tolerability (acceptability of potential side effects) of exidavnemab, at 2 different doses, in patients with Parkinso… Ended

2024-511222-30-00 Multiple System Atrophy 4 2024-10-22
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults Ended

2023-504827-17-00 Chronic migraine 5 2024-03-18
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended

2023-504839-40-00 Episodic Migraine 5 2024-03-18
A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended

2022-501744-15-00 Obesity, Overweight 5 2023-01-23
A study into the efficacy and safety of dazucorilant (CORT113176) in patients with Amyotrophic Lateral Sclerosis Ended

2024-514082-19-00 Amyotrophic Lateral Sclerosis 4 2022-11-04
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Ended

2024-513435-24-01 Neuropathic Pain; Distal Sensory Polyneuropathy 4 2025-06-03
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1) Ended

2024-514559-13-00 Focal Epilepsy 10 2024-11-26
Open-Label Extension Study of PRX012 in Subjects with Alzheimer’s Disease Who Were Enrolled in Study PRX012-101 or PRX012-102 Ended

2023-503729-20-00 Alzheimer’s Disease 3 2024-03-27
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended

2023-505396-71-00 Early Alzheimer’s Disease with Biomarkers of Inflammati 4 2024-03-01
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended

2022-502000-73-00 Focal Onset Seizures 5 2023-08-11
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE study) Ended

2022-501783-18-00 Parkinson’s Disease 4 2023-07-21
C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended

2024-513269-37-00 Migraine attacks with or without aura 6 2023-03-14
C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan… Ended

2024-513270-21-00 migraine headaches with or without aura 6 2023-03-14
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis… Ended

2022-500424-30-00 Parkinson’s disease 4 2022-12-28
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended

2023-505645-12-00 Parkinson's Disease 4 2022-11-28
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the S… Ended

2024-511610-20-00 Alzheimer's Disease 4 2022-11-08
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer’s Disease Ended

2024-512295-36-00 Alzheimer Disease 4 2021-12-06
A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product … Ended

2024-512123-37-00 Parkinson's disease 5 2021-05-27
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended

2023-506918-45-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended

2023-506919-18-00 Mild cognitive impairment (MCI) or mild dementia, both 5 2021-05-17
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended

2023-504990-19-00 Agitation in Patients With Dementia of the Alzheimer's 5 2021-04-06
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended

2023-507303-55-00 Alzheimer Disease 4 2020-09-30